Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barriers To Making Acetaminophen Changes Form Basis For Opposition

This article was originally published in The Tan Sheet

Executive Summary

Implementing an FDA working group's recommendations to reduce acetaminophen-induced liver injury poses significant challenges that the drug industry could cite in arguing against potential restrictions

You may also be interested in...



Acetaminophen Proposals Could Hit Firms Hard Via Sales And Costs

Acetaminophen product manufacturers stand to incur huge costs and reduced revenue opportunities if FDA implements a working group's recommendations to reduce hepatotoxicity risk

OTC Acetaminophen Access Limitations To Be Considered By FDA

FDA is considering examining more extensive ways to inform consumers about the dangers of acetaminophen as well as techniques to limit access to OTC drugs containing the analgesic ingredient.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel